Improving statin prescription through the involvement of nurses in the provision of ASCVD score: a quality improvement initiative in primary care

References

• Godlee F. Lessons from the controversy over statins. Lancet. 2017;389(10074):1100–1101.
   PubMed Web of Science ®Google Scholar
• Winter G. The divided medical opinions of the statin debate updated. Br J Healthcare Manage. 2018;24(7):318–319.
   Google Scholar
• Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769–1781.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Internal Med. 2006;166(21):2307–2313.
   PubMedGoogle Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ (Clin Res Ed). 2009:338:b2376.
   PubMedGoogle Scholar
• Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):Cd004816.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Grundy SM. The 2018 AHA/ACC/Multi-society cholesterol guidelines: looking at past, present and future. Prog Cardiovasc Dis. 2019;62(5):375–383.
   PubMed Web of Science ®Google Scholar
• Pursnani A, Massaro JM, D’Agostino RB Sr, et al. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. 2015;314(2):134–141.
   PubMed Web of Science ®Google Scholar
• Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314(2):142–150.
   PubMed Web of Science ®Google Scholar
• Robinson JG. Lipid management beyond the guidelines. Prog Cardiovasc Dis. 2019;62(5):384–389.
   Web of Science ®Google Scholar
• Van Staa TP, Smeeth L, Ng ES, et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart. 2013;99(21):1597–1602.
   PubMed Web of Science ®Google Scholar
• Fleetcroft R, Schofield P, Ashworth M. Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis. BMC Health Serv Res. 2014;14:414.
   PubMed Web of Science ®Google Scholar
• Hobbs FDR, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19(6):596–604.
   PubMed Web of Science ®Google Scholar
• Lugtenberg M, Zegers-van Schaick JM, Westert GP, et al. Why don’t physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. Implement Sci. 2009;4(1):54.
   PubMedGoogle Scholar
• Dallongeville J, Banegas JR, Tubach F, et al. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol. 2012;19(3):541–550.
   PubMed Web of Science ®Google Scholar
• Shillinglaw B, Viera AJ, Edwards T, et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res. 2012;12:20.
   PubMed Web of Science ®Google Scholar
• Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111(4):499–510.
   PubMed Web of Science ®Google Scholar
• Fung V, Graetz I, Reed M, et al. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. Plos One. 2018;13(2).
   Web of Science ®Google Scholar
• Kazi DS, Virani SS. Implications of cost-effectiveness analyses of lipid-lowering therapies: from the policy-maker’s desk to the patient’s bedside. Prog Cardiovasc Dis. 2019;62:406–413.
   PubMed Web of Science ®Google Scholar
• Sekaran NK, Sussman JB, Xu A, et al. Providing clinicians with a patient’s 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes. BMC Cardiovasc Disord. 2013;13:90.
   PubMed Web of Science ®Google Scholar
• Persell SD, Zei C, Cameron KA, et al. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Internal Med. 2010;170(5):470–477.
   PubMedGoogle Scholar
• Scheitel MR, Kessler ME, Shellum JL, et al. Effect of a novel clinical decision support tool on the efficiency and accuracy of treatment recommendations for cholesterol management. Appl Clin Inform. 2017;8(1):124–136.
   PubMed Web of Science ®Google Scholar
• Aspry KE, Furman R, Karalis DG, et al. Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. J Clin Lipidol. 2013;7(6):546–560.
   PubMed Web of Science ®Google Scholar
• Bertoni AG, Bonds DE, Chen H, et al. Impact of a multifaceted intervention on cholesterol management in primary care practices: guideline adherence for heart health randomized trial. Arch Internal Med. 2009;169(7):678–686.
   PubMedGoogle Scholar
• Virani SS, Akeroyd JM, Ahmed ST, et al. The use of structured data elements to identify ASCVD patients with statin-associated side effects: insights from the department of veterans affairs. J Clin Lipidol. 2019;13(5):797–803. e791.
   PubMed Web of Science ®Google Scholar
• Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich, CT). 2012;14(1):51–65.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.
   PubMed Web of Science ®Google Scholar
• Organization WH, PEPFAR, UNAIDS. Task shifting: rational redistribution of tasks among health workforce teams: global recommendations and guidelines. 2007 [cited 2007]. http://www.who.int/iris/handle/10665/43821
   Google Scholar
• Naughton C, Feely J, Bennett K. A clustered randomized trial of the effects of feedback using academic detailing compared to postal bulletin on prescribing of preventative cardiovascular therapy. Fam Pract. 2007;24(5):475–480.
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Carney G, Taylor S, et al. A randomized trial assessing the impact of a personal printed feedback portrait on statin prescribing in primary care. J Contin Educ Health Prof. 2012;32(3):153–162.
   PubMed Web of Science ®Google Scholar
• Pavlovic J, Greenland P, Deckers JW, et al. Comparison of ACC/AHA and ESC guideline recommendations following trial evidence for statin use in primary prevention of cardiovascular disease: results from the population-based rotterdam study. JAMA Cardiol. 2016;1(6):708–713.
   PubMed Web of Science ®Google Scholar
• Mahmood D, Jahan K, Habibullah K. Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective. J Saudi Heart Assoc. 2015;27(3):179–191.
   PubMed Web of Science ®Google Scholar
• Barkas F, Milionis H, Kostapanos MS, et al. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin. 2015;31(2):221–228.
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Nordestgaard BG, Afzal S, et al. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen general population study. Eur Heart J. 2017;38(8):586–594.
   PubMed Web of Science ®Google Scholar
• Berthold HK, Gouni-Berthold I, Böhm M, et al. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8(1):25.
   PubMedGoogle Scholar
• DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994–2001: a case of agism but not of sexism? Heart. 2003;89(4):417–421.
   PubMed Web of Science ®Google Scholar